A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KESTREL)

Trial Profile

A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KESTREL)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2018

At a glance

  • Drugs Brolucizumab (Primary) ; Aflibercept
  • Indications Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms KESTREL
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 21 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 05 Jul 2018 Planned End Date changed from 17 May 2021 to 8 Jul 2021.
    • 05 Jul 2018 Planned primary completion date changed from 15 Jun 2020 to 6 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top